RAPT
RAPT Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website rapt.com
- Employees(FY) 129
- ISIN US75382E1091
Performance
-13.3%
1W
-50.31%
1M
-84.44%
3M
-69.37%
6M
-83.74%
YTD
-80.81%
1Y
Profile
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Investment Analysis Report: RAPT
Overview
RAPT is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $893.27 million. In this report, we will conduct a comprehensive analysis of RAPT's financial statements over the past three years, focusing on the ...
Technical Analysis of RAPT 2024-05-10
Overview:
In analyzing the technical indicators for RAPT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day MA has been declining steadily, indicating a bearish ...
Recent News & Updates
- 2024-05-13 19:08
- 2024-05-12 21:35
- 2024-05-10 03:46
- 2024-05-09 19:55
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy(Yahoo Finance)
- 2024-05-09 19:54
- 2024-05-09 04:12
- 2024-05-09 03:59
Sector Update: Health Care Stocks Higher Late Afternoon(Yahoo Finance)
- 2024-05-09 02:31
- 2024-05-09 01:53
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024(Investorplace)
- 2024-05-08 20:00
- 2024-04-09 00:00
- 2024-04-08 18:31
3 Biotech Stocks to Dump Before They Go to Zero(Yahoo Finance)
- 2024-03-21 17:39
What Makes RAPT Therapeutics (RAPT) an Investment Choice?(Insidermonkey)
- 2024-03-07 01:52
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023(Investorplace)
- 2024-03-06 19:36
- 2024-03-06 19:00
- 2024-03-05 03:30
- 2024-02-20 07:39
- 2024-02-20 07:30
- 2024-02-20 03:03
- 2024-02-19 22:22
- 2024-02-19 18:58
- 2024-02-19 18:30
- 2024-02-19 18:17
FDA puts hold on Rapt trials of drug for eczema, asthma(Yahoo Finance)
- 2024-02-13 08:00
- 2024-02-12 19:00
- 2024-01-31 08:00
- 2024-01-30 19:00
- 2024-01-02 19:00
- 2024-01-02 08:00
Page 1 of 5
previousnext